Inhibition of vascular smooth muscle cell proliferation

Details Inhibition of vascular smooth muscle cell proliferation Inhibition of vascular smooth muscle cell proliferation

2005-12-27

2005-12-27

Crouch, Deborah (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S093200

Reexamination Certificate

active

06979677

ABSTRACT:
A method for inhibiting restenosis associated with mechanical injury of a blood vessel. An adenoviral vector encoding a suicide gene such as thymidine kinase is directly administered to the injured vessel followed by treatment with a nucleotide analog. The analog is phosphorylated and converted to a cytotoxin by the suicide gene product, resulting in destruction of the rapidly dividing neointimal cells.

REFERENCES:
patent: 6682728 (2004-01-01), Finkel et al.
patent: 9510623 (1995-02-01), None
Brittl, J. A. et al. Clinical Success, Complications and Restenosis Rates with Excimer Laser Coronary Angioplasty. Amer. J. Cardiology. 1992, vol. 70, pp. 1533, 1539.
Barr, E. et al., (1994) Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Therapy 1:15-58.
Chapman, G. et al., (1992) Gene transfer into coronary arteries of intact animals with a percutaneous balloon catheter. Circulation Res. 71(1):27-33.
Culver, K. et al., (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256:1550-1552.
Curiel, D. et al., (1991) Adenovirus enhancement of transferrin-polylysine-mediated gene delivery. Proc. Natl. Acad. Sci. 88:8850-8854.
Davidson, B. et al., (1993) A model system for in vivo gene transfer into the central nervous . . . Nature Genet. 3:219-223.
Elion, G. et al., (1977) Selectivity of action of an antiherpetic agent. 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. 74:12:5716.
Haj-Ahmad, Y. et al., (1986) Development of a helper-independant human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene. J. Virol. 57(3):267-274.
Herbomel, P. et al., (1984) Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma. Cell 39:653-662 (part 2).
Ledley, F. (1991) Clincial considerations in the design of protocols for somatic gene therapy, Human Gene Therapy 2:77-83.
Lee, S. et al., (1993) In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circulation Research 73(5):797-807.
Lemarchand, P. et al., (1992) Adenovirus-mediated transfer of a recombinant human α-antitrypsin cDNA to human endothelial cells. Proc. Natl. Acad. Sci. 89:6482-6486.
Lemarchand, P. et al., (1993) In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circulation Research 72(5):1132-1138.
Mansour, S. et al., (1988) Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature 336:348-352.
Moolten, F. et al., (1990) Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Human Gene Therapy 1:125-134.
Morishita, R. et al., (1993) Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic . . . Proc. Natl. Acad. Sci. 90:8474-8478.
Mullen, C. et al., (1992) Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. 89:33-37.
Mulligan, R. (1993) The basic science of gene therapy. Science 260:926-932.
Plautz, G. et al., (1991) Selective elimination or recombinant genes in vivo with a suicide retroviral vector. The New Biologist 3(7):709-715.
Rakugi, H. et al., (1994) Induction of angiotensin converting enzyme in the neointima after vascular injury. J. Clin. Invest. 93:339-346.
Santoian, E. et al., (1992) Neointimal differences in swine coronary arteries after single balloon injury, balloon reinjury or stent injury. Circulation, Supp. I 86(4) abstract 3187.
Simons, M. et al., (1992) Antisense C-MYB oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359:67-70.
Smith, K. et al., (1982) A new nucleoside analog, 9[[2-hydroxy-1-(hydroxymethyl) ethyl] methyl] guanine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrobial Agents and Chemotherapy 22(1):55-61.
Stratford-Perricaudet, L. et al., (1990) Evaluation of the transfer and expression in mice . . . Human Gene Therapy 1:241-256.
Takeshita, S. et al., (1992) Arterial gene transfer: effect of cell proliferation on transfection efficiency. Circulation, Supp. I 86(4), abstract 0903.
Takeshita, S. et al., (1992) In vivo arterial gene transfer: effect of angioplasty on transfection efficiency in atherosclerotic arteries. Circulation, Supp. I 86(4), abstract 3179.
Willard, J. et al., (1992) Recombinant adenovirus is an efficient vector for in vivo gene transfer and can be preferentially directed at vascular . . . Circulation, Supp. I 86(4) abstract 1880.
Casscells, W. et al., (1992) Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors. Proc. Natl. Acad. Sci. 89:7159-7163.
Guzman, R., et al., (1993) Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation 88(6):2838-2848.
Mazur, W., et al., (1994) Coronary restenosis and gene therapy. Coronary Restenosis and Gene Therapy 21(1):104-111.
Ohno, T., et al., (1994) Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265:781-784.
Takeshita, S., et al., (1994) Increased gene expression after liposome-mediated arterial gene transfer associated with intimal smooth muscle cell proliferation. J. Clin. Invest. 93:652-661.
Venkatesh, L.K., et al., (1990) Selective induction of toxicity to human cells expressing human immunodeficiency virus type I Tat by a conditionally cytotoxic . . . Proc. Natl. Acad. Sci. 87:8746-8750.
Notice of Reasons for Rejection in Japanese Patent Application No. 7-524653 (and English translation), dated Oct. 26, 2004, 3 pages (2 pages).
Makrides, Savvas C., “Components of Vectors for Gene Transfer and Expression in Mammalian Cells.” 1999.Protein Expression and Purification, 17:183-202.
Verman, Inder M. and Nikunji Somia, “Gene therapy-promises, problems and prospects.” 1997.Nature, 389:239-242.
Inverardi, Luca and Camillo Ricordi, “Chapter 56: Cell Transplantation.” 1996.Transplantation Biology: Cellular and Molecular Aspects,pp. 679-687.
Peracchi, Alessio, “Prospects for antiviral ribozymes and deoxyribozymes.” 2004.Rev. Med. Virol.,14:47-64.
Agrawal, Sudhir and Ekambar R. Kandimalla, “Antisense therapeutics: is it as simple as complementary base recognition?” 2000.Molecular Medicine Today,61:72-81.
Chirila, et al., “The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides.” 2002.Biomaterials,23:321-42.
Branch, Andrea D., “A Good Antisense Molecule is Hard to Find.” 1998.Talking Point,TIBS 23:45-50.
Crooke, S.T. (ed.), “Antisense Research and Application.” 1998. Chapters 1 and 2, pp. 1-50.

Affiliated with

Also associated with

Rating

Inhibition of vascular smooth muscle cell proliferation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of vascular smooth muscle cell proliferation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of vascular smooth muscle cell proliferation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3473362